Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

January 30, 2007 09:00 ET

Stem Cell Therapeutics to Present at Canada's Top 10 Life Sciences Companies Investment Forum

CALGARY, ALBERTA--(CCNMatthews - Jan. 30, 2007) -


Recently, Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) was honoured as one of Canada's Top 10 Life Sciences Companies by the Ottawa Life Sciences Council. Accompanying this honour was an opportunity for SCT to present to an audience of top-tier US venture capitalists and investment bankers at an exclusive Investment Forum hosted by the Canadian Consulate General. This week, Dr. Alan Moore, SCT's President and CEO, will present on Tuesday January 30th in Boston, MA then on Thursday February 1st in New York, NY.

"Every opportunity to share the story of Stem Cell Therapeutics Corp's exciting successes with leading venture capitalists and investment bankers in the United States increases the investment community's awareness of our industry leading approach to treating stroke," commented Dr. Alan Moore, President and CEO. "The honour of being named one of Canada's Top 10 Life Sciences companies confirms the respect that SCT continues to garner as we build Canada's leading drug based neurological biotechnology company."

About Canada's Top 10 Life Sciences Competition: The Canada's Top 10 Life Science Companies Competition ( is an annual national competition. The awards are presented to growth-oriented companies and are chosen by an independent international panel of venture capitalists. Based on the jury's expert knowledge of investment in the life sciences sector, the jury selects the companies that offer the best investment and partnership prospects.

About NTx™-265: NTx™-265 is a therapeutic regimen of two drugs being developed by SCT for the treatment of stroke. Human chorionic gonadotropin (hCG) is the first drug administered in the regimen, and aims to increase the number of neural stem cells (NSCs) located in the brain of a patient suffering from a recent stroke. Erythropoietin (EPO) is the second drug administered in the regimen, and aims to promote the differentiation of these newly formed NSCs into new neurons. New neurons thus formed are anticipated to provide benefit to the patient through the replacement of the brain cells that were lost or damaged by the stroke.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. (SCT) is a biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The company's programs aim to repair neurological function lost due to disease or injury. Our currently enrolling phase IIa clinical program for NTx™-265 targets the treatment of stroke by repurposing approved and clinically well defined drugs. The company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information